I. Project Name
Diabetes-associated Autoantibodies Multi-user Detecting Compound Biochip

II. Project Implementation Agency
Shaanxi Chaoying Biological Science and Technology Co., Ltd.

III. Project Description
It is planed to build production workshop and introduce key production equipments and detecting instruments and form the scale production, by using patent technology.

IV. Total Investment and Cooperation Form
Total investment of the project is 30 million Yuan. Cooperation form: joint venture or technology cooperation.

V. Anticipation of Market and Analysis of Investment Return
Diabetes-associated autoantibodies multi-user detecting compound biochip is a kind of new type high-tech biochip detecting technology, which has obtained state invention patent. It mainly applies to the in vitro diagnosis and subtype of diabetes. It can detect GADA, ICA, IA-2 and IAA diabetes autoantibodies in blood serum for several or tens of patients on a chip qualitatively and quantificationally, providing reliable serodiagnosis method for the diagnosis and subtype of diabetes. The more important is that it can find early period diabetes before the occurrence of clinic symptoms. So it can supply a method for early-period diabetes and make it possible to prevent diabetes I. The technology can reduce the cost of 50%-80%. It mainly is applied to diagnosis and subtype of diabetes among people. The number of diabetes patients is increasing by one million a year. The market prospect of the project is broad.

Contact Person: Bu Xue　Wang Geli
Telephone: 029-85254261　029-82373247
Fax: 029-85212721
Address: No.29, South Chang’an Road, Xi’an City, Shaanxi Province
Post Code: 710061
E-mail: info@cybrdi.cn